Hemophilia
Hemophilia ( 15 Questions)
Which drug, used as adjunctive therapy to inhibit the breakdown of fibrin clots, should the nurse consider?
Factor replacement therapy, such as the administration of factor VIII concentrates, is the primary treatment for managing bleeding episodes in patients with hemophilia. However, it does not specifically inhibit the breakdown of fibrin clots, which is the primary role of aminocaproic acid.
Desmopressin acetate (DDAVP) is used to stimulate the release of factor VIII and von Willebrand factor from endothelial cells. While it can help in some cases, it may not be the most effective choice for mucosal bleeding episodes like epistaxis and oral bleeding, where aminocaproic acid is more commonly used.
Aminocaproic acid is an antifibrinolytic medication that inhibits the breakdown of fibrin clots. It is particularly useful in managing mucosal bleeding episodes in patients with hemophilia, such as epistaxis and oral bleeding, by preventing the premature dissolution of clots and promoting hemostasis.
Gene therapy is an emerging treatment for hemophilia, but it does not directly address the breakdown of fibrin clots. It aims to provide a long-term solution by introducing functional clotting factor genes into the patient's body, but it may not be the immediate choice for managing acute bleeding episodes.
Choice A rationale:
Factor replacement therapy, such as the administration of factor VIII concentrates, is the primary treatment for managing bleeding episodes in patients with hemophilia.
However, it does not specifically inhibit the breakdown of fibrin clots, which is the primary role of aminocaproic acid.
Choice B rationale:
Desmopressin acetate (DDAVP) is used to stimulate the release of factor VIII and von Willebrand factor from endothelial cells.
While it can help in some cases, it may not be the most effective choice for mucosal bleeding episodes like epistaxis and oral bleeding, where aminocaproic acid is more commonly used.
Choice C rationale:
Aminocaproic acid is an antifibrinolytic medication that inhibits the breakdown of fibrin clots.
It is particularly useful in managing mucosal bleeding episodes in patients with hemophilia, such as epistaxis and oral bleeding, by preventing the premature dissolution of clots and promoting hemostasis.
Choice D rationale:
Gene therapy is an emerging treatment for hemophilia, but it does not directly address the breakdown of fibrin clots.
It aims to provide a long-term solution by introducing functional clotting factor genes into the patient's body, but it may not be the immediate choice for managing acute bleeding episodes.